Statements (47)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:Company
|
| gptkbp:acquisition |
gptkb:Rexahn_Pharmaceuticals
gptkb:Prolor_Biotech |
| gptkbp:CEO |
gptkb:Phillip_Frost
|
| gptkbp:clinicalTrials |
OPK88003 Phase 3
OPK88003 for Diabetes Rayaldee Phase 3 Rayaldee for Secondary Hyperparathyroidism |
| gptkbp:employeeCount |
~500
|
| gptkbp:focus |
Diagnostics
Therapeutics |
| gptkbp:founded |
2007
|
| gptkbp:founder |
gptkb:Phillip_Frost
|
| gptkbp:headquarters |
gptkb:Miami,_Florida
|
| https://www.w3.org/2000/01/rdf-schema#label |
OPKO Pharmaceuticals
|
| gptkbp:investmentFocus |
$50 million in 2021
|
| gptkbp:partnerships |
gptkb:Eli_Lilly
gptkb:Bristol-Myers_Squibb gptkb:Pfizer gptkb:Teva_Pharmaceuticals |
| gptkbp:products |
gptkb:Rayaldee
gptkb:Vascepa Genetic Testing 4Kscore Test OPK88003 OPK88003 for Cancer OPK88003 for Cardiovascular Disease OPK88003 for Chronic Kidney Disease OPK88003 for Hormonal Disorders OPK88003 for Hyperlipidemia OPK88003 for Hypertension OPK88003 for Insulin Resistance OPK88003 for Metabolic Syndrome OPK88003 for Non-Alcoholic Fatty Liver Disease OPK88003 for Non-Alcoholic Steatohepatitis OPK88003 for Obesity OPK88003 for Type 2 Diabetes Vascepa_for_Cardiovascular_Risk |
| gptkbp:researchAreas |
Cancer
Chronic kidney disease Hormonal disorders |
| gptkbp:revenue |
$100 million (2020)
|
| gptkbp:subsidiary |
gptkb:OPKO_Diagnostics
gptkb:OPKO_Health gptkb:OPKO_Biologics |
| gptkbp:tradedOn |
gptkb:NASDAQ
|
| gptkbp:website |
www.opkopharmaceuticals.com
|